- **Q: What is the current Zacks Rank for AppLovin?
**
Yanuki
ARTICLE DETAIL
AppLovin and CRISPR Therapeutics: Recent Stock Trends and Analyst Ratings | Is Tesla Stock Going to $1,000? | Why the Nasdaq Is Holding Up Better Amid Geopolitical Tensions | Walmart vs BJ's Wholesale: Which Retailer Is a Better Buy? | Institutional Investors Increase Holdings in Invesco QQQ | ExxonMobil (XOM) Stock Analysis: Retail Investors and Market Trends in 2026 | Warren Buffett's Oil Bet: Analyzing Occidental Petroleum (OXY) and the Energy Market in 2026 | Tesla's Risks and Investment Alternatives | Micron Stock: Supply Tightness and Growth Potential in 2026 | AppLovin and CRISPR Therapeutics: Recent Stock Trends and Analyst Ratings | Is Tesla Stock Going to $1,000? | Why the Nasdaq Is Holding Up Better Amid Geopolitical Tensions | Walmart vs BJ's Wholesale: Which Retailer Is a Better Buy? | Institutional Investors Increase Holdings in Invesco QQQ | ExxonMobil (XOM) Stock Analysis: Retail Investors and Market Trends in 2026 | Warren Buffett's Oil Bet: Analyzing Occidental Petroleum (OXY) and the Energy Market in 2026 | Tesla's Risks and Investment Alternatives | Micron Stock: Supply Tightness and Growth Potential in 2026
Finance / Stocks
AppLovin and CRISPR Therapeutics: Recent Stock Trends and Analyst Ratings
This article summarizes the recent stock trends and analyst ratings for AppLovin Corporation (APP) and CRISPR Therapeutics (CRSP), providing an overview for investors to stay informed.
Key Insights
- **AppLovin (APP):** Zacks.com visitors are closely watching AppLovin. The stock has returned +7.6% over the past month, compared to the S&P 500's -0.8% change. AppLovin is expected to post earnings of $1.45 per share for the current quarter, a +116.4% year-over-year change.
- **Why this matters:** Understanding earnings estimate revisions and revenue growth is crucial for assessing AppLovin's potential. Despite a Zacks Rank #3 (Hold), AppLovin's revenue is projected to grow significantly, making it a stock to watch.
- **CRISPR Therapeutics (CRSP):** Leerink Partnrs issued a negative estimate for CRSP earnings, forecasting a loss of ($1.35) per share for Q1 2025, down from their previous estimate of ($1.25). However, other analysts have mixed ratings, with a consensus rating of "Hold" and a consensus price target of $73.11.
- **Why this matters:** The success of Casgevy, CRISPR Therapeutics' first marketed product, is critical. Monitoring sales and updates on its pipeline candidates will provide insights into the company's future performance.
In-Depth Analysis
### AppLovin Corporation (APP) AppLovin is trending due to significant changes in its earnings projections. For the current quarter, earnings are expected to be $1.45 per share, representing a year-over-year increase of +116.4%. Revenue estimates also show strong growth, with a +30.2% increase for the current quarter and approximately +19% for the next fiscal year. However, AppLovin's Zacks Value Style Score is graded F, indicating it may be trading at a premium compared to its peers.
### CRISPR Therapeutics (CRSP) CRISPR Therapeutics' Q1 2025 earnings are under scrutiny following a negative estimate from Leerink Partnrs. The consensus estimate for the quarter's revenues is $5.2 million, with an expected loss of $1.27 per share. The company's stock has lost 0.7% year-to-date. Investors are focused on the sales numbers of Casgevy and updates on other pipeline developments. Several analysts have updated their price targets and ratings, reflecting mixed sentiment on the stock's potential.
FAQ
- **Q: What is the consensus rating for CRISPR Therapeutics?
**
Takeaways
- AppLovin shows strong revenue and earnings growth potential, but its valuation may be high.
- CRISPR Therapeutics' performance is heavily reliant on Casgevy sales and pipeline progress.
- Monitor analyst ratings and earnings reports for both companies to make informed investment decisions.
Discussion
Do you think these trends will continue? Let us know in the comments below! Share this article with others who need to stay ahead of this trend!
Sources
Disclaimer
This article was compiled by Yanuki using publicly available data and trending information. The content may summarize or reference third-party sources that have not been independently verified. While we aim to provide timely and accurate insights, the information presented may be incomplete or outdated.
All content is provided for general informational purposes only and does not constitute financial, legal, or professional advice. Yanuki makes no representations or warranties regarding the reliability or completeness of the information.
This article may include links to external sources for further context. These links are provided for convenience only and do not imply endorsement.
Always do your own research (DYOR) before making any decisions based on the information presented.